Aktiia receives a significant CHF 27 million investment, aiming to revolutionize hypertension care with its advanced wearable technology.

Reports claim that Aktiia, a HealthTech firm from Switzerland, has successfully garnered CHF 27 million in funds, with Redalpine as the main backers along with support from global investors like Khosla Ventures.

This financial boost will help Aktiia’s towards its goal of alleviating the impact of hypertension through AI-powered insights, benefiting over 60,000 users and numerous healthcare bodies.

Aktiia’s CE-marked device, accessible in seven European countries and certified in 44 nations, is two decades in the making. It offers a novel approach to blood pressure monitoring, merging simplicity with machine learning for personalised health insights.

The firm’s expansive data collection, exceeding 300 million points, is instrumental in understanding blood pressure trends and enhancing public health knowledge.

With hypertension affecting over 1.4 billion individuals globally and causing 18 million deaths yearly, Aktiia’s mission is one with large market potential. Will the investors